Infectious disease vaccines
AssigneeModernaTX, Inc.
InventorsGiuseppe Ciaramella, Eric Yi-Chun Huang, Kapil Bahl, Tal Zaks, Sunny Himansu, Sayda Mahgoub Elbashir
Life of this patent
Estimating the term…
Abstract
Aspects of the disclosure relate to nucleic acid vaccines. The vaccines include one or more RNA polynucleotides having an open reading frame encoding one or more Chikungunya antigen(s), one or more Zika virus antigens, and one or more Dengue antigens. Methods for preparing and using such vaccines are also described.
Claims23
-111. (canceled)
A Dengue virus (DENV) messenger ribonucleic acid (mRNA) vaccine, comprising:
- an mRNA polynucleotide comprising an open reading frame encoding a DENV polypeptide;
- and
- a lipid nanoparticle comprising 20-60 mol % cationic lipid, 5-25 mol % neutral lipid, 25-55 mol % sterol, and 0.5-15 mol % polyethylene glycol (PEG)-modified lipid.
-165. (canceled)
(canceled)
(canceled)
-182. (canceled)
-190. (canceled)
-477. (canceled)
A Dengue virus (DENV) messenger ribonucleic acid (mRNA) vaccine, comprising:
- an mRNA polynucleotide comprising an open reading frame encoding a DENV polypeptide;
- and
- a lipid nanoparticle comprising 20-60 mol % ionizable cationic lipid, 5-25 mol % neutral lipid, 25-55 mol % cholesterol, and 0.5-15 mol % polyethylene glycol (PEG)-modified lipid,
- wherein 100% of the uracil in the open reading frame has a chemical modification.
Dependencies are inferred from the claim text.